Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451

GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV infection. Key preclinical properties of GS-9451, including in vitro antiviral activity, selectivity, cross-resistance, and combination activity, as well as pharmacokinetic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yang, Huiling, Robinson, Margaret, Corsa, Amoreena C., Peng, Betty, Cheng, Guofeng, Tian, Yang, Wang, Yujin, Pakdaman, Rowchanak, Shen, Marian, Qi, Xiaoping, Mo, Hongmei, Tay, Chin, Krawczyk, Steve, Sheng, X. Christopher, Kim, Choung U., Yang, Chris, Delaney, William E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3910871/
https://ncbi.nlm.nih.gov/pubmed/23939899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00487-13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados